source
- Coherus trims workforce by 30% as Gyre Therapeutics also cuts staff after acquisitionCoherus Oncology announced a 30% reduction in its workforce as part of a reorganization that narrows its pipeline. The cuts follow a decision to deprioritize a combination therapy across multiple…
- PepGen reports positive Phase 2 data for PGN-EDODM1 in myotonic dystrophyPepGen disclosed that its experimental oligonucleotide therapy PGN-EDODM1 showed encouraging early signals in a Phase 2 cohort of patients with myotonic dystrophy type 1 (DM1). The company said the…